Precision BioSciences, Inc. Common Stock
Compare this stock
DTIL Stock Report Card
$
21%
Performance
Score:
10/100
DTIL returned -79.21% in the last 12 months. Based on SPY's performance of -20.66%, its performance is below average giving it a score of 10 of 100.
Sentiment
Score:
68/100
DTIL had a bullish sentiment score of 68.05% across Twitter and StockTwits over the last 12 months. It had an average of 8.75 posts, 4.76 comments, and 13.29 likes per day.
Technicals
Score:
14/100
DTIL receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
Score:
10/100
DTIL has missed earnings 5 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, DTIL has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
Score:
32/100
DTIL has had a lower than average amount of volatility over the last 12 months giving it a score of 32 of 100.
Precision BioSciences, Inc. Common Stock Summary
Nasdaq / DTIL
Healthcare
Biotechnology
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
DTIL scored poorly on our reportcard. Here are some similar companies and how they performed.
